HRT Financial’s Chemomab Therapeutics CMMB Stock Holding History

HRT Financial’s Portfolio CMMB Stock Details CMMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,395	Closed	-$21K	–	2525
2024 Q3	$21K	Buy	+3,395	New	+$19K	﹤0.01%	2185

Other funds holding CMMB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

RhumbLine Advisers

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

HRT Financial's CMMB Position: Q4 2024 in Review

HRT Financial sold out of Chemomab Therapeutics (CMMB) in Q4 2024, closing a stake of 3,395 shares — an estimated $21K sold.

HRT Financial first reported a position in CMMB in Q3 2024 and held it in 1 quarter. The position peaked at $21K in Q3 2024. 16 funds tracked by Wall St. Rank hold CMMB as of Q4 2024.

HRT Financial reported no remaining Chemomab Therapeutics position as of Q4 2024 after selling out during the quarter.
HRT Financial sold 3,395 Chemomab Therapeutics shares in Q4 2024, an estimated $21K.
HRT Financial first reported a position in Chemomab Therapeutics in Q3 2024 and held it in 1 quarter.
HRT Financial's Chemomab Therapeutics position peaked at $21K in Q3 2024.
16 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2024.

Based on HRT Financial's 13F filing for Q4 2024, filed 14 Feb 2025.